Clinical Trial

Atrasentan in Patients With IgA Nephropathy

Name: Atrasentan in Patients With IgA Nephropathy — clinical trial record (NCT04573478)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ALIGN

Active, Not Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

Trial Details

NCT Number	NCT04573478
Lead Sponsor	Novartis Pharmaceuticals
Conditions	IgA Nephropathy, Immunoglobulin A Nephropathy
Enrollment	404 participants
Start Date	2020-12-11
Primary Completion	2028-04-14 (estimated)
Study Completion	2028-04-14 (estimated)
Updated on ClinicalTrials.gov	2026-06-04